Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Institute of Chronic Illnesses is a non-profit research organization founded by Mark and David Geier, primarily known for its controversial work regarding the etiology and treatment of autism spectrum disorder. The institute promoted the Geier protocol, which hypothesized that mercury from vaccines interacted with testosterone to cause autism, leading to the off-label use of leuprolide (Lupron) and chelation therapy. These treatments were widely condemned by the scientific community for lacking empirical support and posing significant health risks to children. The organization's activities eventually led to the revocation of Mark Geier's medical license in multiple jurisdictions and the cessation of its clinical operations. Despite its controversial history, the institute remains a significant case study in the intersection of fringe medical theories and patient advocacy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Institute of Chronic Illnesses.